Navigation Links
Organon Extends MetaCore License and Adds MetaLink
Date:10/2/2007

ST. JOSEPH, Mich., Oct. 2 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Organon, the human health care business unit of Akzo Nobel, have extended their GeneGo software and database licenses. In addition to extending their MetaCore license, Organon has also added MetaLink so that they can upload their own interaction data and visualize it in the context of MetaCore's manually curated content.

GeneGo offers easy to use automated workflows that casual users can use and these are now also available through their new product 1-2-3 workflow which is a "pay as you go" business model. GeneGo also covers human, mouse, rat, dog, worm, chicken, fly, chimpanzee and yeast which is very important for our customers.

"GeneGo has demonstrated the capability to develop a good pharma oriented bioinformatics tool in the past years," said Peter Groenen, project manager for pharmacogenetics at Organon. "We have now started to use their software for more advanced projects to support our translational medicine efforts."

"Organon has been a good, loyal GeneGo customer for years and we are pleased they have extended their license," said Julie Bryant, GeneGo's VP of Business Development. "We have received good development feedback from Organon over the years and implemented their ideas in MetaCore."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 2.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) and MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NimbleGen extends research market reach
2. TomoTherapy extends reach to Germany
3. Third Wave says patent extends IP reach
4. `Single-sales factor extends tax treatment to tech, service firms
5. Alumni Association extends database help to university
6. Small-Tree extends G5 networking platform to G4, Windows and Linux
7. WARF expands license agreement with Advanced Cell Technology
8. GenTel licenses next generation cancer research
9. Metavante broker technology licensed to ING Bank
10. Companies are still taking software license
11. Third Wave licenses Innogenetics tech to settle lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
(Date:3/22/2017)... LEXINGTON, Mass. , March 22, 2017   ... collections, today announced that Doctors Pathology Service ... mid-Atlantic region of the United States ... the Delaware Health Information Network (DHIN) to ... researchers. The novel program, announced in ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com ... ... cancer conditions are being pressured as of late due to ... cancer pain management has a dramatic impact on patient,s quality ... and development activities for identifying new forms of opioid formulations ...
(Date:3/22/2017)... --  Boston Biomedical , an industry leader in the ... stemness pathways, today announced its Board of Directors has ... Officer, effective April 24, 2017. Ms. ... FACP, who has led Boston Biomedical since he founded ... Biomedical has grown from a "garage startup" without technology ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
Breaking Biology News(10 mins):